Tags

Type your tag names separated by a space and hit enter

Eletriptan in migraine.
Expert Rev Neurother. 2005 Jan; 5(1):43-53.ER

Abstract

Migraine is a highly prevalent, chronic and disabling illness in which the gap between practice guideline recommendations and actual clinical practice remains wide. Eletriptan, similar to other triptans, is a potent 5-HT(1B/1D) receptor agonist with a high selectivity for cranial versus coronary artery constriction and favorable pharmacokinetic profile. An extensive program of double-blind, placebo-controlled, head-to-head comparator trials has demonstrated the superior efficacy of eletriptan compared with the combination of ergotamine and caffeine, and selected oral triptans for the acute treatment of migraine. Eletriptans tolerability profile makes it a good choice as a first-line treatment of migraine. An early treatment study suggests that treatment of mild headache is associated with unusually high sustained pain-free rates and a tolerability profile that is equivalent to placebo.

Authors+Show Affiliations

Department of Neurology, University of Essen, Hufelandstr. 55, D45122 Essen, Germany. h.diener@uni-essen.de

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Review

Language

eng

PubMed ID

15853473

Citation

Diener, Hans-Christoph. "Eletriptan in Migraine." Expert Review of Neurotherapeutics, vol. 5, no. 1, 2005, pp. 43-53.
Diener HC. Eletriptan in migraine. Expert Rev Neurother. 2005;5(1):43-53.
Diener, H. C. (2005). Eletriptan in migraine. Expert Review of Neurotherapeutics, 5(1), 43-53.
Diener HC. Eletriptan in Migraine. Expert Rev Neurother. 2005;5(1):43-53. PubMed PMID: 15853473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Eletriptan in migraine. A1 - Diener,Hans-Christoph, PY - 2005/4/28/pubmed PY - 2006/4/19/medline PY - 2005/4/28/entrez SP - 43 EP - 53 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 5 IS - 1 N2 - Migraine is a highly prevalent, chronic and disabling illness in which the gap between practice guideline recommendations and actual clinical practice remains wide. Eletriptan, similar to other triptans, is a potent 5-HT(1B/1D) receptor agonist with a high selectivity for cranial versus coronary artery constriction and favorable pharmacokinetic profile. An extensive program of double-blind, placebo-controlled, head-to-head comparator trials has demonstrated the superior efficacy of eletriptan compared with the combination of ergotamine and caffeine, and selected oral triptans for the acute treatment of migraine. Eletriptans tolerability profile makes it a good choice as a first-line treatment of migraine. An early treatment study suggests that treatment of mild headache is associated with unusually high sustained pain-free rates and a tolerability profile that is equivalent to placebo. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/15853473/Eletriptan_in_migraine_ L2 - https://www.tandfonline.com/doi/full/10.1586/14737175.5.1.43 DB - PRIME DP - Unbound Medicine ER -